View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Location: CPMC (San Francisco)
Please contact: ClinicalResearch@sutterhealth.org about study AstraZeneca Capitello
Genomic Health Oncotype DX AR-V7
Investigators: Vijay Suhag, M.D., Kristie A. Bobolis, M.D., David S Yee, M.D., MPH, Nitin Rohatgi, MD, Kristin N. Arreola, M.D., Sivakumar Reddy, M.D., Brian K. Kim, M.D, Rajeswari Chellappah, M.D.